GDF/BMP Antagonists for Pulmonary Hypertension Vascular Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for pulmonary hypertension (PH) do not provide a cure and fail to directly address vascular remodeling and muscularization of blood vessels, highlighting a need for effective treatments that can reduce the severity and progression of the disease.
Innovation Solution
The use of GDF/BMP antagonists, such as soluble ActRIIA polypeptides and ALK4:ActRIIB heterodimers, to inhibit signaling pathways and reduce blood pressure, cardiac hypertrophy, and vascular remodeling in PH models, including PAH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If current PH therapies (pulmonary vasodilators, phosphodiesterase-5 inhibitors) are administered, then blood pressure reduction is achieved, but vascular remodeling and muscularization of blood vessels are not addressed
Solution Approach 1:
The patent extracts and targets the specific signaling pathway (GDF/BMP signaling through ActRII receptors) that drives vascular remodeling and muscularization, separating this pathological process from general blood pressure regulation. By administering soluble ActRII polypeptides that specifically bind and neutralize GDF/BMP ligands, the invention addresses the root cause of vascular remodeling without affecting overall blood pressure homeostasis.
Solution Approach 2:
The soluble ActRII polypeptide acts as an intermediary molecule that binds to GDF/BMP ligands (such as activins and BMPs) and prevents them from interacting with cellular ActRII receptors on pulmonary vascular smooth muscle cells. This intermediary approach blocks the profibrotic and pro-hypertrophic signaling cascade that leads to vascular remodeling and muscularization, thereby addressing the underlying pathology rather than just the hemodynamic consequence.
2Reliability
If GDF/BMP antagonists are administered, then vascular remodeling and muscularization are reduced, but therapeutic complexity increases compared to existing drugs
Solution Approach 1:
The soluble ActRII polypeptide serves multiple therapeutic functions simultaneously: it blocks GDF/BMP signaling to prevent vascular remodeling, inhibits smooth muscle cell proliferation, reduces muscularization of pulmonary arterioles, and prevents fibrosis. This multi-functionality is achieved through the polypeptide's ability to bind multiple GDF/BMP ligands (activins, BMPs, GDFs) that share the same receptor, thereby simplifying the therapeutic approach despite the complexity of the underlying pathology.
Solution Approach 2:
The invention changes the therapeutic parameter from general vasodilation (affecting all vascular smooth muscle cells) to specific blockade of GDF/BMP signaling (affecting only GDF/BMP-responsive cells). This parameter change is achieved by using a biologic agent (soluble receptor polypeptide) that selectively targets the pathological signaling pathway, thereby achieving tissue-specific therapy with reduced off-target effects and simplified dosing regimens.
3Duration of action of moving object
If long-term PH treatment is provided, then symptom management is improved, but disease severity and progression are not reduced
Solution Approach 1:
The soluble ActRII polypeptide performs preliminary action by blocking GDF/BMP signaling before vascular remodeling and muscularization can progress. By administering the agent early in the disease course, the therapy prevents the activation of profibrotic pathways and the subsequent development of irreversible vascular structural changes. This preliminary blockade of the pathological signaling cascade stops disease progression at its inception rather than managing symptoms after damage has occurred.
Solution Approach 2:
The invention applies preliminary anti-action by using the soluble ActRII polypeptide to preemptively neutralize GDF/BMP ligands before they can bind to cellular receptors and initiate the signaling cascade that leads to vascular remodeling. This anti-action occurs at the molecular level, blocking the ligand-receptor interaction that triggers pathological changes, thereby preventing disease progression before it can manifest as structural vascular damage or symptomatic deterioration.
Data Source
AI summary
In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.